Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Histones are the main structural proteins of eukaryotic chromatin. Histone acetylation/ deacetylation are the epigenetic mechanisms of the regulation of gene expression and are catalyzed by histone acetyltransferases (HAT) and histone deacetylases (HDAC). These epigenetic alterations of DNA structure influence the action of transcription factors which can induce or repress gene transcription. The HATs catalyze acetylation and the events related to gene transcription and are also responsible for transporting newly synthesized histones from the cytoplasm to the nucleus. The activity of HDACs is mainly involved in silencing gene expression and according to their specialized functions are divided into classes I, II, III and IV. The disturbance of the expression and mutations of HDAC genes causes the aberrant transcription of key genes regulating important cancer pathways such as cell proliferation, cell-cycle regulation and apoptosis. In view of their role in cancer pathways, HDACs are considered promising therapeutic targets and the development of HDAC inhibitors is a hot topic in the search for new anticancer drugs. The present review will focus on HDACs I, II and IV, the best known inhibitors and potential alternative inhibitors derived from natural and synthetic products which can be used to influence HDAC activity and the development of new cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012 · cited 4×
“modifications can also occur in the side chains of the internal histones of the nucleosome [14].”
BackgroundInfluentialThe fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
DNA methylation and its basic function
Moore, L. D., Le, T., & Fan, G. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.112 · Cited by 4,906 · cited 2×
“as acetylation, the mono-, di- and tri-methylation of lysins and the phosphorylation of serines [9].”
BackgroundNan, X., Ng, H.-H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., & Bird, A. (1998) · Nature · doi:10.1038/30764 · Cited by 3,440
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047 · cited 2×
“effector genes such as GADD45A and p21 [161].”
BackgroundAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 3×
“histones, facilitating the access of transcription factors to gene promoters [180].”
BackgroundInfluentialHistone acetylation in chromatin structure and transcription
Grunstein, M. (1997) · Nature · doi:10.1038/38664 · Cited by 2,884 · cited 1×
“This constant maintenance requires specific levels of control, and is undertaken by transcriptional regulators which bind to selected sequences in the DNA, inducing the production of proteins responsible for the structural modifications in chromatin and the consequent binding of regulators to DNA, causing epigenetic m…”
BackgroundSirtuins as regulators of metabolism and healthspan
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3293 · Cited by 2,008 · cited 2×
“neurodegenerative diseases and aging [215].”
BackgroundThe first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · cited 4×
“MDM2 can recruit HDAC1, promoting the deacetylation of p53, and this silencing can more quickly interrupt the function of this protein when its target genes are no longer necessary [164].”
BackgroundInfluentialA Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829 · cited 1×
“HDAC1 and HDAC2 were discovered in 1996 [69,70], while HDAC3 was described in 1997 [71].”
BackgroundStructures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · cited 2×
“These inhibitors are divided into five subgroups based on their chemical structure: short-chain fatty acids that include hydroxamic acids, benzamides, cyclic peptides, and sirtuin inhibitors [19,176,191].”
BackgroundHistone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542 · cited 1×
“promotes cell death and inhibits angiogenesis in different tumor cell lines in in vitro studies [268] (see”
BackgroundGregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
Health-promoting components of fruits and vegetables in the diet.
Liu, R. H. (2013) · Advances in Nutrition · doi:10.3945/an.112.003517 · Cited by 1,310
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206 · cited 2×
“These compounds are classified into two large classes, isoform-selective inhibitors and pan-inhibitors, which act against all class I HDACs [134,190].”
BackgroundAggarwal, B. B., & Sung, B. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.11.002 · Cited by 1,140 · cited 1×
“Another potential HDACi is curcumin (diferuloylmethane), a polyphenol and the active component of turmeric (Curcuma longa) [250], which is widely known for its diverse pharmacological activities against various diseases, including cancer [251–255].”
BackgroundZhang, Y., Ng, H.-H., Erdjument-Bromage, H., Tempst, P., Bird, A., & Reinberg, D. (1999) · Genes & Development · doi:10.1101/gad.13.15.1924 · Cited by 1,103 · cited 1×
“HDAC1/2 cannot bind directly to DNA without interacting with other specific molecules and its activity was reduced in the absence of this binding [90].”
BackgroundHDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL
Shivdasani, R. A., Mayer, E. L., & Orkin, S. H. (1995) · Nature · doi:10.1038/373432a0 · Cited by 938 · cited 1×
“The deletion of the SCL/TAL1 transcription factor, for example, resulted in the inability to generate hematopoietic precursors and caused embryo death in mice [151].”
BackgroundRegulation of nucleosome dynamics by histone modifications
Zentner, G. E., & Henikoff, S. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2470 · Cited by 923 · cited 2×
“This weakened binding can facilitate the action of transcription factors in this altered region, inducing or repressing gene transcription [13].”
BackgroundThree proteins define a class of human histone deacetylases related to yeast Hda1p
Grozinger, C. M., Hassig, C. A., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4868 · Cited by 770 · cited 1×
“HDAC4, 5 and 6 were characterized in the same year, HDAC7 in 1999 [72] and HDAC8 in 2000 [73,74].”
BackgroundEssential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760 · cited 3×
“In addition, an increase in HDAC2 and HDAC3 expression is observed in HDAC1-deficient cells, which is unable to compensate for the loss of HDAC1, suggesting a unique function of this enzyme [49].”
BackgroundInfluentialFischle, W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, W., & Verdin, E. (2002) · Molecular Cell · doi:10.1016/s1097-2765(01)00429-4 · Cited by 754 · cited 3×
“is dependent on the interaction with the SMRT/NCoR–HDAC3 complex [128].”
BackgroundInfluentialGao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111871200 · Cited by 744 · cited 2×
“Like HDAC10, HDAC11 was discovered in 2002 [78] and so far they are the least studied and understood HDACs.”
BackgroundChemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720 · cited 4×
“These compounds are classified into two large classes, isoform-selective inhibitors and pan-inhibitors, which act against all class I HDACs [134,190].”
BackgroundInfluentialChromatin deacetylation by an ATP-dependent nucleosome remodelling complex
Tong, J. K., Hassig, C. A., Schnitzler, G. R., Kingston, R. E., & Schreiber, S. L. (1998) · Nature · doi:10.1038/27699 · Cited by 692
Class II histone deacetylases: versatile regulators
Verdin, E., Dequiedt, F., & Kasler, H. G. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00073-8 · Cited by 664 · cited 2×
“HDACs of this class can induce the conversion of cell signaling by presenting conservative serine residues in the regulatory N-terminal domains, with reversible phosphorylation [130].”
BackgroundChemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1759 · Cited by 659
MDM2–HDAC1-mediated deacetylation of p53 is required for its degradation
Ito, A., Kawaguchi, Y., Lai, C., Kovacs, J. J., Higashimoto, Y., Appella, E., & Yao, T. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf616 · Cited by 570 · cited 2×
“MDM2 can recruit HDAC1, promoting the deacetylation of p53, and this silencing can more quickly interrupt the function of this protein when its target genes are no longer necessary [164].”
BackgroundUnraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases
Lahm, A., Paolini, C., Pallaoro, M., Nardi, M. C., Jones, P., Neddermann, P., Sambucini, S., Bottomley, M. J., Lo Surdo, P., Carfı́, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706487104 · Cited by 566 · cited 2×
“regulating the microtubules of the cytoskeleton [129].”
BackgroundTaori, K., Paul, V. J., & Luesch, H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja7110064 · Cited by 428
Histone deacetylase 8 in neuroblastoma tumorigenesis
Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398 · cited 2×
“HDAC8 I 377 Nucleus, Mitochondria and cytoplasm Neuroblastoma, melanoma, hematological tumors [58,65,66]”
BackgroundMBD2/NuRD and MBD3/NuRD, Two Distinct Complexes with Different Biochemical and Functional Properties
Le Guezennec, X., Vermeulen, M., Brinkman, A. B., Hoeijmakers, W. A. M., Cohen, A., Lasonder, E., & Stunnenberg, H. G. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.3.843-851.2006 · Cited by 340 · cited 1×
“For example, MBD2 and MBD3 are related proteins with a methyl-CpG consensus binding domains that are found exclusively in NuRD complexes [120].”
BackgroundHu, E., Chen, Z., Fredrickson, T., Zhu, Y., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Sung, C.-M., Liu, R., & Winkler, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m908988199 · Cited by 309 · cited 1×
“HDAC4, 5 and 6 were characterized in the same year, HDAC7 in 1999 [72] and HDAC8 in 2000 [73,74].”
BackgroundKelly, R. D. W., & Cowley, S. M. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130010 · Cited by 297 · cited 4×
“This diversity and the incorporation of sequence-specific DNA-binding proteins can modulate their function and cellular context activity [96].”
BackgroundInfluentialSmits, A. H., Jansen, P. W. T. C., Poser, I., Hyman, A. A., & Vermeulen, M. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks941 · Cited by 258 · cited 1×
“The nucleosome remodeling deacetylase complex (NuRD), also known as Mi-2, according to stoichiometry data [114,115], is composed of one copy of the CHD3 (Mi2α) or CHD4 (Mi2β) proteins (chromodomain, helicase, DNA binding domain), one HDAC1 or HDAC2, three MTA1/2/3 (metastasis associated), one copy of MBD2 and MDB3 pro…”
BackgroundMolecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10
Guardiola, A. R., & Yao, T.-P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109861200 · Cited by 253 · cited 1×
“However, in HDAC10, this domain has no known function [135].”
BackgroundMoreno, D. A., Scrideli, C. A., Cortez, M. A. A., De Paula Queiroz, R., Valera, E. T., Da Silva Silveira, V., Yunes, J. A., Brandalise, S. R., & Tone, L. G. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08301.x · Cited by 208
Regulation of histone deacetylase 2 by protein kinase CK2
Tsai, S.-C., & Seto, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204149200 · Cited by 196 · cited 2×
“The Sin3A complex has also been associated with other enzymatic activities depending on the molecules of the interaction [87,108,109].”
BackgroundIsolation and Characterization of Mammalian HDAC10, a Novel Histone Deacetylase
Kao, H.-Y., Lee, C.-H., Komarov, A., Han, C. C., & Evans, R. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108931200 · Cited by 193 · cited 1×
“HDAC10, on the other hand, has no association with other proteins forming complexes, which indicates that the involvement in the transcription control occurs by other means [77].”
BackgroundTargeting Class I Histone Deacetylases in a “Complex” Environment
Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.006 · Cited by 180
Kelly, R. D. W., Chandru, A., Watson, P. J., Song, Y., Blades, M., Robertson, N. S., Jamieson, A. G., Schwabe, J. W. R., & Cowley, S. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-32927-9 · Cited by 138
HDAC inhibitors still need a home run, despite recent approval
Guha, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4583 · Cited by 120 · cited 2×
“Although HDACis are showing important activities, mainly oncological, their adverse effects and cytotoxicity are still serious and do not present selective inhibition among HDACs isoforms [216].”
BackgroundIdentification and Characterization of a Novel p300-mediated p53 Acetylation Site, Lysine 305
Wang, Y.-H., Tsay, Y.-G., Tan, B. C.-M., Lo, W.-Y., & Lee, S.-C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212574200 · Cited by 92
Cited by
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222
Li, Y., Sang, S., Ren, W., Pei, Y., Bian, Y., Chen, Y., & Sun, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113874 · Cited by 77
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Luo, Y., & Li, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228828 · Cited by 62
The Many Faces of Microbiota-Gut-Brain Axis in Autism Spectrum Disorder
Gonçalves, C. L., Doifode, T., Rezende, V. L., Costa, M. A., Rhoads, J. M., & Soutullo, C. A. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122357 · Cited by 42
Metadata
- Authors
- Verza, F. A., Das, U., Fachin, A. L., Dimmock, J. R., & Marins, M.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-06-23
- Volume
- 12
- Issue
- 6
- Pages
- 1664
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3036185872
- Cited by
- 143
- References
- 47
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.